Emerald BioStructures Achieves Second Milestone and Expands Collaboration with UCB, Inc.
(BUSINESS WIRE)--Emerald BioStructures, a leading provider of fragment-based drug discovery services, announced today that it has successfully achieved the second milestone in its collaboration with UCB on the structure-based discovery of small molecule modulators of undisclosed targets.